| 32.03 0.44 (1.39%) | 11-11 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 38.84 | 1-year : | 40.64 |
| Resists | First : | 33.26 | Second : | 34.79 |
| Pivot price | 32.07  |
|||
| Supports | First : | 30.77 | Second : | 25.6 |
| MAs | MA(5) : | 31.95 |
MA(20) : | 32.24 |
| MA(100) : | 35.35 |
MA(250) : | 35.12 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 23.8 |
D(3) : | 27.9 |
| RSI | RSI(14): 46.3 |
|||
| 52-week | High : | 45.29 | Low : | 27.34 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ LEGN ] has closed above bottom band by 45.9%. Bollinger Bands are 79.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 24 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 32.62 - 32.8 | 32.8 - 32.97 |
| Low: | 30.83 - 31.07 | 31.07 - 31.29 |
| Close: | 31.69 - 32.03 | 32.03 - 32.35 |
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates, which are in Phase I clinical trials for the treatment of gastric cancer and T cell lymphoma. In addition, it is developing CAR-T product candidates targeting CD20/CD22/CD19 for the treatment of non-hodgkins lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.
Tue, 11 Nov 2025
Legend Biotech Q3 2025 Earnings Preview - MSN
Tue, 11 Nov 2025
Legend Biotech (LEGN) Anticipates Strong Q3 Earnings Growth - GuruFocus
Tue, 11 Nov 2025
Legend Biotech (NasdaqGS:LEGN) Valuation in Focus After FDA Label Update Highlights CARVYKTI Survival Benefit - simplywall.st
Mon, 10 Nov 2025
H.C. Wainwright Remains Bullish on Legend Biotech (LEGN), Cites Solid Growth Trajectory for CARVYKTI Therapy - Insider Monkey
Mon, 10 Nov 2025
H.C. Wainwright Remains Bullish on Legend Biotech (LEGN), Cites Solid Growth Trajectory for CARVYKTI Therapy - MSN
Sun, 09 Nov 2025
15 Stocks Set to Explode in 2026 - Insider Monkey
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 185 (M) |
| Shares Float | 163 (M) |
| Held by Insiders | 1.2 (%) |
| Held by Institutions | 47.3 (%) |
| Shares Short | 11,400 (K) |
| Shares Short P.Month | 9,690 (K) |
| EPS | -1.78 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.61 |
| Profit Margin | -40.9 % |
| Operating Margin | -8.6 % |
| Return on Assets (ttm) | -7.9 % |
| Return on Equity (ttm) | -29.7 % |
| Qtrly Rev. Growth | 36.7 % |
| Gross Profit (p.s.) | 0.53 |
| Sales Per Share | 4.31 |
| EBITDA (p.s.) | -1.14 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -275 (M) |
| Levered Free Cash Flow | -259 (M) |
| PE Ratio | -18 |
| PEG Ratio | 0 |
| Price to Book value | 5.7 |
| Price to Sales | 7.41 |
| Price to Cash Flow | -21.53 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|